

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Please cancel claims 1-10, 12-14, 18, 20-21, 28-51, 54, 56 and 58-66, without prejudice, amend the remaining claims and add new claims 67-69 as follows.

Claims 1-10 (canceled)

Claim 11. (previously presented) An isolated human monoclonal antibody comprising human heavy chain and human light chain variable regions comprising the amino acid sequences shown in SEQ ID NO: 7 and SEQ ID NO: 8, respectively.

Claims 12-14 (canceled).

Claim 15. (currently amended) The antibody of ~~any one of the preceding claims~~ claim 11 which completely inhibits M21 cell adhesion to vitronectin.

Claim 16. (currently amended) The antibody of ~~any one of the preceding claims~~ claim 11, comprising a human IgG heavy chain and a human kappa light chain.

Claim 17. (currently amended) The antibody of ~~any one of the preceding claims~~ claims 11, comprising an IgG1 or IgG3 heavy chain.

Claim 18. (Canceled)

Claim 19. (Currently amended) A pharmaceutical composition comprising the antibody of ~~the preceding claims~~ claim 11 and a pharmaceutically acceptable carrier.

Claim 20. (Canceled)

Claim 21. (Canceled).

Claim 22. (currently amended) A composition according to claim 19 wherein the antibody is combined with an anti-neoplastic agent selected from the group consisting of a radiopharmaceutical, an estrogen receptor modulator, a retinoid, a topoisomerase inhibitor, a cytotoxin, an alkylating agent, a nitrogen mustard, a nitrosourea, an antimetabolite, a mitotic inhibitor, and a radiosensitizer.

Claim 23. (currently amended) A composition according to claim 22 wherein the ~~anti-neoplastic agent~~ alkylating agent is dacarbazine.

Claim 24. (currently amended) An immunoconjugate comprising the antibody according to any one of ~~the preceding claims~~ claim 11 linked to a therapeutic agent.

Rule  
1.126  
Claim 25. (previously presented) The immunoconjugate of claim 24 wherein the therapeutic agent is a cytotoxin.

Claim 26. (previously presented) The immunoconjugate of claim 25 wherein the therapeutic agent is a radioisotope.

Claim 27. (currently amended) A pharmaceutical composition comprising the immunoconjugate of ~~any one of claims 24-26~~ claim 24 and a pharmaceutically acceptable carrier.

Claims 28-51 (Canceled).

Claim 52. (currently amended) An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising a solution or a lyophilized form of at least one isolated human anti-alpha-V subunit antibody according to any one of ~~claims 1-18~~ claim 11.

Claim 53. (previously presented) The article of manufacture of claim 52, wherein said container is a component of a parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelular, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal delivery device or system.

Claim 54 (Canceled).

Claim 55. (currently amended) ~~At least one anti-alpha-V subunit~~ An isolated human monoclonal antibody according to claim 11 produced by a method according to claim 54 comprising transfecting a host cell or transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts said antibody with a nucleic acid molecule encoding such antibody and recovering the antibody from cell, animal or plant.

Claim 56. (Canceled).

Claim 57. (currently amended) ~~An alpha-V subunit~~ isolated human monoclonal antibody according to ~~claim 56~~ claim 11, wherein said antibody binds ~~alpha-V subunit~~ purified human  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  integrins with an affinity of at least one selected from at least  $10^{-9}$  M, at least  $10^{-10}$  M, at least  $10^{-11}$  M, or at least  $10^{-12}$  M.

Claims 58-66 (Canceled).

Claim 67 (newly added) An isolated human monoclonal antibody according to claim 57, wherein said antibody binds purified human  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  integrins with an affinity of at least  $10^{-9}$  M.

Rule

1.126

Claim 68 (newly added) An isolated human monoclonal antibody according to claim 57, wherein said antibody binds purified human  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  integrins with an affinity of at least  $10^{-10}$  M.

<sup>69</sup>  
Claim ~~68~~ (newly added) An isolated human monoclonal antibody according to claim 57, wherein said antibody binds purified human  $\alpha_v\beta_3$  or  $\alpha_v\beta_5$  integrins with an affinity of at least  $10^{-11}$  M.

<sup>70</sup>  
Claim ~~68~~ (newly added) An isolated human monoclonal antibody according to claim 57, wherein said antibody binds human  $\alpha_v\beta_6$  integrin in HEK-293 cells (Human embryonal kidney cells, ATCC CRC-1573) transfected with cDNA constructs to overexpress  $\alpha_v\beta_6$  integrin.

<sup>71</sup>  
Claim ~~70~~ (newly added) The human monoclonal antibody of claim 11 which is an IgG1kappa antibody.